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ORIGINAL RESEARCH REPORT
Equine Mesenchymal Stromal Cells Retain
a Pericyte-Like Phenotype
Cristina L. Esteves,1 Tara A. Sheldrake,1 Lucy Dawson,1 Timothy Menghini,1 Burgunde Elisabeth Rink,1
Karin Amilon,1 Nusrat Khan,2 Bruno Pe´ault,2,3 and Francesc Xavier Donadeu1
Mesenchymal stem/stromal cells (MSCs) have been used in human and equine regenerative medicine, and interest in
exploiting their potential has increased dramatically over the years. Despite significant effort to characterize equine
MSCs, the actual origin of these cells and how much of their native phenotype is maintained in culture have not been
determined. In this study, we investigated the relationship between MSCs, derived from adipose tissue (AT) and
bone marrow (BM), and pericytes in the horse. Both pericyte (CD146, NG2, and aSMA) and MSC (CD29, CD90,
and CD73) markers were detected in equine AT and colocalized around blood vessels. Importantly, as assessed by
flow cytometry, both pericyte (CD146, NG2, and aSMA) and MSC (CD29, CD44, CD90, and CD105) markers were
present in a majority (‡90%) of cells in cultures of AT-MSCs and BM-MSCs; however, levels of pericyte markers
were variable within each of those populations. Moreover, the expression of pericyte markers was maintained for at
least eight passages in both AT-MSCs and BM-MSCs. Hematopoietic (CD45) and endothelial (CD144) markers
were also detected at low levels in MSCs by quantitative polymerase chain reaction (qPCR). Finally, in coculture
experiments, AT-MSCs closely associated with networks produced by endothelial cells, resembling the natural
perivascular location of pericytes in vivo. Our results indicate that equine MSCs originate from perivascular cells and
moreover maintain a pericyte-like phenotype in culture. Therefore, we suggest that, in addition to classical MSC
markers, pericyte markers such as CD146 could be used when assessing and characterizing equine MSCs.
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Introduction
Horses and humans are the two species in which interestin the therapeutic use of mesenchymal stem/stromal
cells (MSCs) is highest. In the horse, the past decade saw a
dramatic increase in the use of MSC preparations [1,2], in
particular for repair ofmusculoskeletal injuries [3–6], whereby
conventional treatments have limited efficacy. The main
clinical application of equine MSCs has been tendon and lig-
ament repair [7–10], but other conditions such as joint disease
and laminitis are also being considered [11]. Importantly, be-
cause musculoskeletal pathophysiology in horses resembles
that in humans, the U.S. Food and Drug Administration has
approved the use of horses as a large animal preclinical
model, which broadens the relevance of the findings obtained
in equine.
Equine MSCs used clinically are mainly derived from bone
marrow (BM) and adipose tissue (AT) [2,12,13]. BM samples
are processed using a density gradient to isolate the mononu-
cleated cell fraction, whereas AT extracts are obtained by col-
lagenase digestion [14]. Both BM and AT extracts contain
heterogeneous cell populations that can be cultured and char-
acterized for their MSC properties. Contrary to human MSCs,
there are no standard guidelines to define equine MSCs and,
therefore, the minimum criteria established in 2006 by the In-
ternational Society for Cellular Therapy (ISCT) are commonly
applied [15]. Specifically, ISCT guidelines state that MSCs
must grow adherent to plastic and have the ability to differentiate
into adipocytes, osteocytes, and chondrocytes. Guidelines for
adipose-derived MSC surface markers have been more recently
updated [16] to include CD44 in addition to CD105, CD73, and
CD90, while CD45 and CD31 must be absent. In relation to
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equine MSCs, although trilineage differentiation is usually
demonstrated, a variable immunophenotype is often reported for
cells of different tissue origins, and additional makers such as
CD29 are being considered to characterize MSCs [1,17–21].
Despite significant work to characterize their properties, the
precise in vivo origin of equineMSCs andwhether theymaintain
their original phenotype in culture have not been determined.
Pericytes are perivascular cells, also known as Rouget or mural
cells, and are embedded in the basement membrane of small
blood vessels, capillaries, and microvessels [22–24]. In humans,
isolated pericytes expressing CD146, NG2, PDGFRb, and
aSMAhave been described as a native source ofMSCs [25], but
it is still not clear how the pericyte phenotype is maintained in
cultured MSCs obtained from heterogeneous cell extracts of AT
and BM.
To further understand the nature of equine MSCs, in this
study we investigated the relationship between equine MSCs
and pericytes both in native tissues and in culture, including
a comparison between AT-MSCs and BM-MSCs.
Materials and Methods
Samples
Samples were obtained immediately postmortem from
eight adult horses. All animal procedures were carried out
according to the U.K. Home Office Animals (Scientific Pro-
cedures) Act 1986 with approval by the Ethical Review
Committee, University of Edinburgh. Tissues (AT, BM,
and large blood vessels) were kept on ice until cell ex-
traction or were frozen in cold isopentane mounted in op-
timum cutting temperature compound (OCT; VWR Chemicals,
Leicestershire, United Kingdom) for immunohistochemistry
(IHC). Subcutaneous AT was obtained by dissection from
the abdominal region close to the linea alba.
Immunohistochemistry
Samples were processed in a Leica CM1900 cryostat,
allowed to air dry, and processed right away or kept fro-
zen at -80C. For staining, tissues were fixed in ice cold
acetone–methanol (50:50) and antibodies were prepared in
diluent (003118; Invitrogen-Thermo Fisher Scientific, Paisley,
United Kingdom) and, after staining, slides were mounted
in fluoroshield with DAPI (Sigma-Aldrich, St Louis, MO).
Primary antibodies used in the study are listed in Table 1
and isotype controls were mouse IgG1k 400101 (BioLegend,
San Diego, CA), mouse IgG1 MCA928F (AbD Serotec-
BioRad, Kidlington, United Kingdom), mouse IgG1 MAB002
(R&D Systems, Minneapolis, MN), mouse IgG1k 557273
(BD, Oxford, United Kingdom), and rabbit PRABP01 (AbD
Serotec-BioRad). Secondary antibodies were AF488 con-
jugated (A11008 and A11029) and AF568 conjugated
(A110037 and A10042). Isotypes and secondary antibodies
alone were used as controls. Micrographs were produced
using a Zeiss LSM710 confocal or Leica DMLB fluores-
cent microscope.
Cell extraction and culture
AT samples were minced and digested for 45min with
collagenase II (1mg/mL; Gibco-Thermo Fisher Scientific)/
BSA (3.5%) at 37C under agitation (100 rpm). Collagenase
activity was stopped by addition of Dulbecco’s modified
Eagle’s medium with 20% fetal bovine serum (FBS)
(Thermo Fisher Scientific) and the lipid layer was removed
after separation by gravity. BM-MSCs were obtained by
aspiration of sternum marrow followed by centrifugation
on a density gradient, and the mononucleated cell layer
was harvested. Endothelial cells were harvested by tying
up both ends of a small piece of blood vessel that had
been washed with phosphate-buffered saline (PBS) and
filled with collagenase II (1 mg/mL). After a 45-min di-
gestion, endothelial cells were collected and cultured.
To determine colony-forming unit-fibroblasts (CFU-F),
cells were seeded at a density of 1, 5, and 25 cells/cm2 and
allowed to grow for 11 days in tissue culture dishes of 55 cm2
growth surface area. Colonies were observed by staining for
phosphatase alkaline activity using a commercial kit (86R-
1KT; Sigma-Aldrich). In brief, cells were washed twice with
PBS, then fixed with paraformaldehyde-citrate acetate buffer
for 30 s, and washed again with PBS, to which the alkaline
dye mixture was added.
RNA extraction and gene expression analyses
Cultured cells were harvested in Trizol (Thermo Fisher
Scientific) and RNA was reverse transcribed to cDNA using
SuperScript III (18080-044; Invitrogen-Thermo Fisher Scien-
tific). Quantitative polymerase chain reaction (qPCR) was
performed using SensiFAST SYBR Lo-ROX kit (Bioline,
London, United Kingdom) and equine primers designed by us,
Table 1. List of Antibodies Used in This Study
Antibody Reactivity Company Cat. number Conjugate Clone
CD29 Human, cow BioLegend 303002/303015 Purified/AF488 TS2/16
CD44 Horse AbD Serotec MCA1082GA Purified CVS18
CD73 Rat BD 551123 Purified 5F/B9
CD90 Rat BD 554895/561973 Purified/FITC OX7
CD105 Human, horse, monkey AbD Serotec MCA1557T Purified SN6
CD144 Human, mouse, rat, cow AbD Serotec AHP628Z Purified Polyclonal
CD146 Human, pig Biorad MCA2141F FITC/AF647 OJ79c
NG2 Human R&D MAB2585/
FAB2585A
Purified/APC LHM-2
aSMA Mouse, rat, chicken,
guinea pig, cow,
dog, human
Abcam ab5694 Purified Polyclonal
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specifically to recognize PDGFRb (5¢-GTGCCTACAAAG
GCTCCCAT-3¢ and 5¢-CACAGTGGGATCTGGCACAA-3¢),
CD144 (5¢-TCTGCAGGACATCAATGACAAC-3¢ and 5¢-
CTTCAG GCACGGCAAATACG-3¢), NG2 (5¢-CGCATCA
TTGGGCCCTACTT-3¢ and 5¢-GCTGTTCCACCTCTCTCC
AG-3¢), and 18S (5¢-GCTGGCACCAGACTTG-3¢ and 5¢-
GGGGAATCAGGGTTCG-3¢), or obtained from the litera-
ture [20]. Reactions proceeded in a MX3005P qPCR system
(Stratagene, CA). Results were analyzed with Stratagene
MxPro software and normalized to 18S levels quantified in the
same samples.
Flow cytometry
Flow cytometry was performed in samples of AT-MSCs and
BM-MSCs stained at 4C with primary antibody for 1 h and,
when necessary, with secondary antibody for 30min. Primary
antibodies are listed in Table 1. Secondary antibodies were
AF488 conjugated (A11029; Invitrogen), AF405 conjugated
(Ab175654; AbCam, Cambridge, United Kingdom), or APC-
Cy7 conjugated (sc-3847; Santa Cruz Biotechnologies, Paso
Robles, CA).
Isotype controls used were mouse IgG1k 400101 (BioLe-
gend), mouse IgG1 MCA928A647 (AbD Serotec-BioRad),
mouse IgG1 MAB002, and IgG1 IC002A (R&D Systems),
or rabbit PRABP01 (AbD Serotec-BioRad). Sytox blue
(Thermo Fisher Scientific) was used as live cell stain. Iso-
types and secondary antibodies alone were used as controls.
Samples were run on a BD LSRFortessa or BD FACSAria
Fusion (BD Biosciences, San Jose, CA) and data were ana-
lyzed on FlowJo_V10 (LLC, Ashland).
Cell differentiation
AT-MSCs and BM-MSCs were differentiated into adi-
pocytes, osteocytes, and chondrocytes. Adipogenesis was
induced by DMEM/F-12 (Life technologies) containing 7%
rabbit serum (Gibco-Thermo Fisher Scientific), 3% FBS
(Invitrogen), 1% penicillin/streptomycin (Gibco-Thermo
Fisher Scientific), 1 mM dexamethasone (Sigma Aldrich),
0.5 mM IBMX (Sigma Aldrich), 10 mg/mL insulin (Sigma
Aldrich), and 100 mM indomethacin (Sigma Aldrich). Adi-
pocytes were stained with Oil Red O (Sigma-Aldrich) as
described before [26]. Chondrogenesis and osteogenesis
were induced using StemPro differentiation kits following
manufacturer’s instructions for 18 days (A10071-01 and
A10072-01, respectively; Life Technologies). Chondrocyte
pellets were embedded in Histogel (HG-4000; Invitrogen)
and paraffin, and cut at 8 mm thickness. Slides were dewaxed
and rehydrated and Alcian blue solution (1%) was added to
the slide and incubated overnight. Then, the stain was re-
moved and the slides were washed. Neutral red (1%)
FIG. 1. IHC of equine AT sec-
tions showing staining for the
pericyte markers, CD146 (A), NG2
(B), aSMA (C), and the MSC
markers, CD29 (D) and CD90 (E).
CD144 was used as endothelial
marker (red; A, B, D, E). Colocal-
ization of pericyte (NG2 and
CD146) and MSC markers (CD146
and CD73; F, G, respectively) in
yellow (left panel) from the overlap
of green (middle panel) and red
(right panel) individual antibody
fluorescence. DAPI was used to
stain nuclei. Scale bar, 10 mm, is
indicated by white bars. IHC, im-
munohistochemistry; MSC, mes-
enchymal stem/stromal cell. Color
images available online at www
.liebertpub.com/scd
MSCS RETAIN A PERICYTE-LIKE PHENOTYPE 3
solutionwas added and incubated for 1min and rinsed in water.
Absolute ethanol and xylene were used to dehydrate the slides
that were mounted with pertex. Osteogenic cultures were wa-
shed with PBS and fixed with PFA (4%) for 15min and stored
in PBS at 4C. After washing with water, Alizarin Red S
(A5533; Sigma-Aldrich) prepared in water with pH adjusted to
4.2 was added to cover the cellular monolayer. The plate was
incubated at room temperature in the dark for 10min and
washed with water. Negative controls were produced with
nondifferentiated cells and micrographs were taken in an Ax-
iovert 25 Inverted Microscope (Zeiss, Oberkochen, Germany).
Angiogenesis
The fluorescent dyes PKH26 (20mM) and PKH67 (20mM)
(both from Sigma-Aldrich) were used to label AT-MSC (red)
and equine endothelial cells (green). Once labeled, cells were
resuspended in EGM-2 medium and seeded on ibiTreat m-
Slides (IB-81506; Thistle Scientific) coated with matrigel.
Pictures were taken using a Zeiss Live Cell Observer/
Deconvolution system.
Statistical analysis
Results are shown as mean – standard error of the mean,
and were analyzed by Students’ t-test or two-way analysis of
variance followed by Tukey test using GraphPad Prim 6.0
software (GraphPad Software, La Jolla, CA). Significance
was set at P < 0.05.
Results
Localization of pericytes in equine AT
The relative location of pericyte (CD146, NG2, and aSMA)
andMSC (CD29, CD73, and CD90)markers was examined by
immunohistochemistry in equine adipose or testis (Fig. 1 and
Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/scd). CD146 and NG2 were
detected around small blood vessels as evidenced by the
presence of adjacent endothelial cells stained with CD144
(Fig. 1A, B) in agreement with previous results from human
samples [25,27]. Other cell types in the tissue (Supplementary
Fig. S1A, B) were negative for these pericyte markers, as well
as the isotypes and secondary antibody controls (Supplemen-
tary Fig. S1D–F), showing cross-reactivity by CD146 andNG2
antibodies. aSMA was also perivascular (Fig. 1C), whereas
none of the five different PDGFRb antibodies tested gave a
specific signal (data not shown). For the classical MSCs, anti-
bodies tested before in equine tissues [19], were also located
around small blood vessels, as shownby the results of CD29 and
CD90 (Fig. 1D, E). In addition, dual staining with antibodies
against NG2 and CD29, or CD146 and CD73 (Fig. 1F, G and
Supplementary Fig. S1B) confirmed the colocalization of peri-
cytes and MSC markers in equine AT and in testis, consistent
with the notion that pericytes may give rise to MSCs in culture.
Characterization of AT-MSCs and BM-MSCs
Extracts from equine AT and BM were obtained by colla-
genase digestion and density gradient, respectively, and the
resulting cells grew in uncoated tissue culture vessels, showing
a characteristic spindled-like morphology (Fig. 2A). To test the
ability of AT-MSCs andBM-MSCs to formCFU-Fs, cells were
seeded at 1, 5, and 25 cells/cm2. After 11 days, both AT-MSCs
and BM-MSCs formed colonies (49.5– 13.9 and 43.5– 10.5
CFU-F, respectively, for cells seeded at a density of 5 cells/cm2),
which were positive for alkaline phosphatase (Fig. 2B), as
reported before for human MSCs [28] and pericytes [25,29].
Both AT-MSCs and BM-MSCs were multipotent. Adi-
pogenic capacity was evidenced by Oil Red O staining,
showing accumulation of lipids in the cytoplasm (Fig. 2C),
osteogenesis was evidenced by the dark red staining of
calcium deposits produced by Alizarin Red S (Fig. 2D) and
chondrogenesis was shown by Alcian blue staining of car-
tilage matrix in cell micromasses (Fig. 2E).
The expression of typical MSC markers was confirmed by
flow cytometry (Fig. 3A) by using antibodies that have
previously been validated or used in other equine studies
[19,20]. The results showed that ‡99% of the cells were
positive for CD29, CD44, CD90, and CD105 in both AT-
MSCs and BM-MSCs. qPCR analyses confirmed compara-
ble expression of CD44, CD73, CD90, and CD105 by the
FIG. 2. Photomicrograph of cultured AT-MSCs and BM-
MSCs (A) that generated AP-positive colonies when grown
at low density (1, 5, and 25 cells/cm2) for 11 days (B) and
differentiated into adipocytes (C), osteocytes (D), and
chondrocytes (E) observed by Oil Red O, Alizarin Red S,
and Alcian blue counterstained with Neutral red, respec-
tively. Inset shows detail of the chondrocyte micromasses.
AT, adipose tissue; BM, bone marrow. Color images
available online at www.liebertpub.com/scd
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two cell types (Fig. 3B). Moreover, the hematopoietic ma-
ker, CD45, was not detected in AT-MSCs but was present at
low levels in all BM-MSC cultures. Low levels of expres-
sion of the endothelial cell marker, CD144, were observed
in both AT-MSCs and BM-MSCs, whereas CD31 was not
detected. Overall, these results showed that our cells ful-
filled the criteria for MSCs and confirmed that AT-MSC and
BM-MSC preparations are heterogeneous in nature.
AT-MSCs and BM-MSCs express
pericyte markers in culture
Following from our finding that MSC and pericyte
markers colocalize in equine tissues (Fig. 1), we wanted to
determine whether the expression of pericyte markers would
be maintained by MSCs in culture by using complementary
data from flow cytometry and qPCR, and to do this we
validated further the pericyte antibodies (Supplementary
Fig. S2). Flow cytometry showed the pericyte markers,
CD146 and NG2, to be highly expressed (‡94.6%) in AT-
MSCs and BM-MSCs, whereas aSMA was present at
slightly lower levels (‡89.9%). Histograms showed a broad
distribution in the fluorescence intensity of CD146- and
NG2-positive cells, suggesting highly variable expression
among individual cells (Fig. 4A). To confirm these findings
and at the same time determine whether pericyte markers
were maintained by MSCs during extended culture, we
quantified the expression of CD146, NG2, and PDGFRb by
qPCR in AT-MSCs and BM-MSCs at passages 2 and 8
(Fig. 4B). All pericyte markers were expressed at similar
levels in AT-MSCs and BM-MSCs, and although CD146
and PDGFRb levels remained unchanged across passages in
both MSC types, NG2 expression decreased (P< 0.05) at
passage 8 in BM-MSCs.
MSCs adopt a periendothelial location in vitro
To assess whether MSCs maintain functional character-
istics of perivascular cells, we cocultured AT-MSCs and
endothelial cells on matrigel. In endothelia-only cultures, a
cell network was incipient after seeding and became in-
creasingly organized with dense strands (Fig. 5). AT-MSCs
FIG. 3. Flow cytometry histograms of AT-MSCs and BM-MSCs (A; upper and lower panels, respectively) showing
positive staining of most cells for the MSC markers, CD29, CD44, CD90, and CD105 (dark line; ‡99% cells for all
antibodies by detection of AF488 conjugate or FITC conjugate). Signal from isotype controls is shown by the gray peak and
unstained curves were omitted for simplicity. (B) Results of quantitative polymerase chain reaction (qPCR) analysis of the
MSC markers, CD44, CD73, CD90, and CD105, and (C) the endothelial markers, CD31 and CD144, and the hematopoietic
marker, CD45, in AT-MSCs and BM-MSCs. All results are shown as mean – SEM; n = 3 animals. *P< 0.05 and
**P < 0.005. AU, arbitrary units; ND, not detected; SEM, standard error of the mean.
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FIG. 4. (A) Flow cytometry histograms showing the proportions of AT-MSCs and BM-MSCs (upper and lower panels,
respectively) that are positive for staining with the antibodies CD146-AF647, NG2-APC, and aSMA (with secondary
AF405 conjugated). Isotype controls are shown by the gray peak and unstained curves are omitted for simplicity. (B)
Results of qPCR analysis of CD146, NG2, and PDGFRb in AT-MSCs and BM-MSCs at passages 2 (P2) and 8 (P8). All
results are shown as mean – SEM; n = 3 animals. *P< 0.05.
FIG. 5. Microphotographs of cul-
tured equine endothelial cells (Endo,
labeled with the green fluorescent
PKH67), AT-MSCs (MSCs, labeled
with the red fluorescent PKH26)
or both cell types together (En-
do+MSCs) obtained after seeding on
matrigel. Arrows point to MSCs as-
sociated with endothelial cells. Col-
or images available online at www
.liebertpub.com/scd
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cultured in the absence of endothelia cells organized
quickly, forming dense cores of cells that were interlinked
by thin bridging extensions, which became more condensed.
In cocultures, AT-MSCs tended to colocate with endothelial
cells beginning even before a network formed and, impor-
tantly, at later stages, AT-MSCs remained closely associated
with the endothelial networks, resembling the perivascular
location of pericytes in vivo (Fig. 1).
Discussion
Clinical MSCs are commonly obtained through culture of
crude (nonpurified) extracts, typically from BM or AT. Al-
though equine MSCs are widely used clinically, there is a
significant lack of knowledge regarding their in vivo origin,
identity, and maintenance of original phenotype in culture.
This has hindered efforts to characterize equine MSCs as well
as exploit their full therapeutic potential. Studies performed in
humans [25,27,30] have shown that pericytes, a cell type
surrounding small blood vessels throughout the body, express
MSC markers both in situ and during culture after isolation.
Moreover, cultured pericytes can differentiate into several
mesenchymal derivatives, findings all of which implicate
pericytes as native precursors of MSCs. However, whether
nonpurified equine MSC preparations used clinically maintain
original characteristics of pericytes in culture has not been
studied. In this project, we investigated the relationship be-
tween equine MSCs and pericytes by performing analyses
both in equine tissues and in cultured MSCs. Our results shed
new light on the nature of these elusive cells by indicating that
native pericytes are progenitors of equine MSC populations
derived in culture. This conclusion is based on our findings
that (1) typical markers of pericytes and MSCs colocalized
around small blood vessels in equine AT, (2) cultured equine
AT-MSCs and BM-MSCs both expressed pericyte markers
over extended culture (up to passage 8), and (3) equine MSCs
closely associated with endothelia cell networks in cocultures.
Flow cytometry analyses revealed most cells in both AT-
MSCs and BM-MSCs preparations contained CD146 and NG2.
The presence of CD146 mRNA in equine MSCs has been pre-
viously reported [20]. Our results showed a broad distribution in
fluorescence intensity of both CD146 and NG2 in equineMSCs,
with a small fraction of cells having no or very low expression,
indicating cell heterogeneity and/or potential loss of pericyte
immunophenotype in culture. Nonetheless, mRNA levels for
these markers were sustained up to passage 8, except for NG2 in
BM-MSC populations. Around 10% of MSCs were negative for
aSMA, a finding that may be explained by the observation that a
subset of pericytes do not naturally express this marker [25,31].
Consistent with their pericyte immunophenotype was the ten-
dency of equine AT-MSCs to closely associate with endothelial
cell networks in cocultures, a property that has been reported
before for MSCs [32,33] and pericytes [34,35] in human but not
in horse. Based on our results showingmaintenance of a pericyte
phenotype byMSCs over extended culture, itmay be desirable to
include pericyte markers, for example, CD146, in the panel of
markers currently used to immunophenotype equine MSCs.
Since perivascular cells expressing CD146 are present in most
body tissues [25,30,34], CD146 may serve as a universal MSC
marker. In addition, CD146 has been identified as a marker of
multipotency in human MSCs [36], which could provide obvi-
ous advantages for tissue regeneration purposes.
We detected CD29, CD44, CD90, and CD105 in a ma-
jority of cells in AT-MSC and BM-MSC populations, in
agreement with many [18,19,20,37] but not all [38] previous
studies. A limited number of studies have compared the ex-
pression of MSC markers between AT-MSCs and BM-MSCs.
In accordance with the present data, no significant differences
were found in transcript levels of CD73, CD90, and CD105
[39] between these two cell types, whereas higher expression
of CD44 and CD90 was reported for BM-MSCs than for AT-
MSCs [20]. These discrepancies may be related to the use of
different extraction methods, cell culture conditions, analytical
techniques, and cell immunophenotyping reagents. As already
suggested [19,21], better standardization of techniques used to
collect, culture, and analyze equine MSCs is needed before
results from different studies can be meaningfully compared.
According to ISCT guidelines, all MSCs should be negative
for CD45, and AT-MSCs should additionally lack CD31.
Several previous studies did not detect CD45 in equine MSCs
using flow cytometry [19,39–41]; however, we (this study) and
Radcliffe et al. [18] did detect this marker by qPCR. CD31 (or
other endothelial markers) has not been commonly considered
in the characterization of equine MSC preparations, in part,
because ISCT recommendations on CD31 were just introduced
in 2013 [15,16]. Although we did not detect CD31 in our
preparations, CD144 (another endothelial marker) was present
at low levels in all MSCs. Overall, these results demonstrate
the heterogeneity of equine MSCs from different sources and
highlight the necessity to use different approaches to fully
characterize these preparations, an important consideration
because cell heterogeneity may significantly impact the out-
come of treatments [36,42].
In conclusion, our results from the analysis of equine
tissues and MSC preparations in culture indicate that equine
MSCs originate from pericytes and that they maintain a
pericyte immunophenotype in culture. Taken together with
data available in other species, our results indicate that the
isolation and selective culture of pericytes from crude ex-
tracts could provide a means to increase the quality and
clinical efficacy of equine MSC preparations. Although se-
lective harvesting and in vitro expansion of equine pericytes
may be challenging, the findings obtained in this study
represent an initial step toward that goal.
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